Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Rafaela Nasser Veiga et al, 2024, Journal of Molecular Medicine CrossRef
Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists
Amy K. Wesa et al, 2008, The Journal of Immunology CrossRef
Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region
Jie Liu et al, 2022, Analytical Cellular Pathology CrossRef
Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets
João Figueira Scarini et al, 2024, Frontiers in Oncology CrossRef
Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
Areti-Maria Vasilogianni et al, 2023, Frontiers in Oncology CrossRef
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
Ahmed F. Salem et al, 2018, Journal of Medicinal Chemistry CrossRef
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer
Charles N. Landen et al, 2006, JNCI: Journal of the National Cancer Institute CrossRef
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
Jun Hasegawa et al, 2016, Cancer Biology & Therapy CrossRef
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
Jill Wykosky et al, 2008, Molecular Cancer Research CrossRef
Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
Scott A. Hammond et al, 2007, Cancer Research CrossRef
Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder
Shaji Abraham et al, 2006, Clinical Cancer Research CrossRef
Eph-modulated Cell Morphology, Adhesion and Motility in Carcinogenesis
Sabine Wimmer-Kleikamp et al, 2005, IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) CrossRef